About
Matthew Singleton is postdoctoral researcher in the Cancer Neuroscience laboratory at QIMR Berghofer. He completed his PhD studies at The University of Queensland in 2024 where his project focused on investigating the response of the paediatric brain cancer, Medulloblastoma, to CDK4/6 inhibitors using both in vitro and patient-derived orthotic xenograft models.
He joined the Cancer Neuroscience laboratory in 2024 to investigate the targeting of quiescent glioblastoma stem cells by utilising patient-derived organoid models. His PhD and postdoctoral research has provided him with extensive experience in utilising a variety of models of brain cancer (cell lines, patient-derived organoids and patient-derived orthotopic mouse models) to generate clinically translatable research.